Archive - Two Natural Cap

March 2025

Solid BioSciences, Sarepta, and Regenxbio ($sldb, $srpt, $rgnx)

Gene therapies for the largest gene in the body, protein-protein interaction choices, and the importance of capsid design.

Mar 19 •

Two Natural Capital

February 2025

Blackstone: A Test in Generating Alpha at Scale $bx

Perpetual Capital, Private Credit, and the Power of a Brand Name

Feb 27 •

Two Natural Capital

January 2025

Long-read vs Short-read, Cancer Testing, and Debt Paydown vs Innovation

Jan 23 •

Two Natural Capital

December 2024

Sarepta Therapeutics: From Exon-Skipping to Gene Therapy $srpt

Business model shifts, incentives to innovate, and a flywheel for rare diseases

Dec 12, 2024 •

Two Natural Capital

October 2024

Sophia Genetics: The Benefits/Drawbacks of Sequencer Agnosticism $soph

Akre Capital, Illumina/Ultima/Element, and Data-Driven Healthcare.

Oct 30, 2024 •

Two Natural Capital

September 2024

Tempus AI: A (Tentative) Short Thesis $tem

Company name changes, reimbursement decisions, and clinical AI vs GitHub Copilot

Sep 25, 2024 •

Two Natural Capital

August 2024

July 2024

Dyno Therapeutics - AAV Vectors for Gene Therapy

Thanks to all who are reading this week - disagreements and corrections are welcome.

Jul 30, 2024 •

Two Natural Capital

June 2024

Ginkgo Earnings: Why Biotech Platforms are Hard $DNA

Thanks to all who are reading this week - criticism is welcome.

Jun 27, 2024 •

Two Natural Capital

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts